tbuckley/cabot-search huggingface dataset:
Left bundle-branch block. Prognosis in acute myocardial infarction
Authors: L. Gould
Journal: JAMA (1973)

Of 27 patients with left bundle-branch block following acute myocardial infarction, five died. Left bundle-branch block was present on admission in 26 patients, and subsequently appeared in one. Fourteen of 16 patients who did not have a temporary pacemaker placed prophylactically survived the acute myocardial infarction. Of the 22 survivors, 16 are still alive, an average of 12.7 months after the acute myocardial infarction. Thus, left bundle-branch block in acute myocardial infarction does not affect prognosis, and is not an indication for prophylactic insertion of a transvenous pacemaker or of a permanent pacemaker.
Teratological Research Using In Vitro Systems. II. Rodent Limb Bud Culture System
Authors: Leonard Friedman
Journal: Environmental Health Perspectives (1987)

This review represents a compilation of information related to the rodent limb bud culture system from approximately 80 publications after 1969 and conversations with workers in the field. Most of these papers and book chapters refer exclusively to studies with the mouse limb bud. Sections in this review include historical review, end point measurements, activating systems, types of compounds studied and dose response, reproducibility, statistical analysis, equipment and personnel requirements, mechanisms, and summary.
NOSTRUM ADVERTISEMENTS IN THE RELIGIOUS PRESS.
Journal: JAMA (1906)

Now that many newspapers are refusing advertisements of questionable proprietary medicines, it may not be amiss to call attention to the shortcomings of another class of journals in which these advertisements are more or less prominent, namely, the religious and semi-religious publications.<i>A priori</i>it might be expected that publications of this character would exclude from even their advertising pages any statement which was obviously lacking in truth, so far as human experience is able to judge of truth. A glance over the adverrising pages of the available religious and semi-religious journals shows that this is far from being the case. Discrimination must be made, however, between certain high-class theological publications and semi-religious journals (as the<i>Outlook</i>, for example) on the one hand and the cheaper weekly semi-religious sheets on the other. The former are clean in their advertising, the latter are far from being so. The class of medical
Exposure to environmental tobacco smoke in California
Authors: C. Collett
Journal: JAMA (1993)

<h3>In Reply.</h3> —Mr Collett claims that our conclusion calling for a smoke-free workplace is not justified by the reported data. He cites studies funded by the tobacco industry indicating that a smoke-free workplace is not necessary to protect nonsmokers from exposure to ETS since special ventilation systems can minimize contamination by ETS from designated smoking areas to nonsmoking areas. The issue is whether there is a threshold under which exposure to ETS is safe and over which it is harmful to the health of a nonsmoker. We know of no such safe level of ETS exposure. In fact, the Environmental Protection Agency has just classified ETS as a class A carcinogen on a par with asbestos and radon. Thus, we take the position that any exposure to ETS at all is to be avoided. In our study, we asked whether during the past 2 weeks the respondent had anyone smoke
Error in Funding/Support
Journal: JAMA Network Open (2019)

Sana Syed, MD, MS; Mohammad Al-Boni, PhD; Marium N. Khan, MD; Kamran Sadiq, MD; Najeeha T. Iqbal, PhD; Christopher A. Moskaluk, MD, PhD; Paul Kelly, MD, FRCP; Beatrice Amadi, MD, MMed; S. Asad Ali, MD, MPH; Sean R. Moore, MD, MS; Donald E. Brown, PhD
Coronary artery occlusion resulting from blunt trauma
Authors: T. Stern
Journal: JAMA (1974)

SEVERE, frontal, nonpenetrating chest trauma is a common event that frequently results in a variety of intrathoracic injuries. The occurrence of a blunt injury to a major coronary artery resulting in coronary occlusion has been rarely reported. A cause and effect relationship between blunt chest injury and coronary occlusion may, at times, be difficult to prove because of the presence of preexisting atheromatous stenosis in the coronary vessels.<sup>1-5</sup>We report the occurrence of complete obstruction of the left anterior descending coronary artery following severe, frontal, nonpenetrating chest injury sustained in an automobile accident. <h3>Report of a Case</h3> A 16-year-old white teen-ager was admitted to Baptist Memorial Hospital on Aug 25, 1972, following an automobile accident. He was riding in the seat next to the driver and recalled striking his chest and chin on the steering wheel and dashboard. He sustained multiple facial fractures with obstruction of the upper airway
Treatment for Individuals With HIV/AIDS Following Release From Prison
Authors: Keith Barton
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Birmingham Workhouse Infirmary
Journal: BMJ (1859)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Birmingham Workhouse Infirmary Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Evaluation of a new antituberculous agent. Ethambutol hydrochloride (Myambutol)
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study
Authors: Birgit Bremer, Olympia Anastasiou, Svenja Hardtke, Florin Alexandru Caruntu, Manuela Gabriela Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gurel, Ramazan Idilman, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George Papatheodoridis, Monica Radu, Michael P. Manns, Markus Cornberg, Cihan Yurdaydin, Heiner Wedemeyer
Journal: Journal of Hepatology (2020)
The Gin 192Arg polymorphism of the paraoxonase gene (PON1) is a genetic risk factor for coronary artery disease Yiwen Liu-Stratton, Gregory M. Eaton, James P. Bacon, Raymond D. Magorien, Pascal J. Goldschmidt-Clermont, Glen E. Cooke. The Ohio State University, Columbus, OH, Duke University, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Pseudorheumatoid Nodules
Authors: John D. Burrington
Journal: JAMA (1971)

<h3>To the Editor.—</h3> I read with interest the BRIEF REPORT "Isolated, Subcutaneous, Rheumatic-like Nodules" by Miller (<b>215</b>:1151,1971). I would take exception to the statement in this communication that in no reported case has the proper diagnosis been made preoperatively (<i>Pediatrics</i><b>45</b>:474-478, 1970). I am currently observing a number of children with typical subcutaneous pseudorheumatoid nodules and have observed the entire natural evolution of these nodules in several children. Of the children I am now following up, only one has the typical cutaneous manifestations of granuloma annulare. I believe that Miller's mistaken impression that the diagnosis is never made preoperatively stems from the fact that it is difficult to report a series of cases based on clinical impression. However, the factors of the disease entity involving pseudorheumatoid nodules are now well enough known so that all affected children should be followed up without biopsy. The importance of these nodules
GPs need guidance on protecting their computers from viruses
Authors: B. Fox
Journal: BMJ (2001)

Two week rule for cancer referralsReducing waiting times from diagnosis to treatment might be more effectiveEditor-In their editorial on the two week rule for cancer referrals Jones et al discuss the fact that steps to meet the target for "urgent" referrals have led to a doubling of waiting time for "routine" cases. 1 This is exactly the result we would expect from our calculations modelling waiting times with a Monte Carlo model based on Poisson fluctuations in demand. 2 To sustain a waiting time below two weeks, capacity needs to exceed mean demand by approximately two patients a week for a wide range of values of mean demand.This applies to any appointment, including those for diagnostic and staging procedures, as well as for treatment.Applying this excess capacity to a subgroup of urgent referrals is inherently less efficient than applying it to reduce the waits for all patients.If a fast track for urgent referrals is created by transferring resources from routine cases, this is likely to lead to demand exceeding capacity for routine cases and hence to ever increasing waiting times.These calculations assume that variations are due to random fluctuations in a constant demand, which is an effective model for oncology referrals. 2There is some evidence from dermatology that reductions in waiting times lead to increase in demand, negating the benefit of increased resources. 3t might also apply to referrals for suspected cancer, in which case the extra capacity required will exceed our calculations.This effect should not apply to the number of cases of diagnosed cancer, which will be limited by the incidence of the disease.This suggests that resources may be more effectively targeted at reducing the waiting times from diagnosis to treatment than on reducing the time from referral by a general practitioner to diagnosis.
Poster Session 4: Hepatitis C: Preclinical Development
Journal: Hepatology (2014)

Purpose/Background: Since they display a high genetic barrier to drug resistance and are pan-genotypic, nucleoside HCV inhibitors are the preferred candidates in the pursuit to achieve 100% sustained virological response (SVR) with one molecule.Despite the wide adoption of sofosbuvir as the only nucleoside analog approved by the FDA for HCV infection, ribavirin or another direct acting agent is required to achieve high SVR.Herein, we report, for the first time, the discovery of β-D-2'-C-methyl-4-N-hydroxycytidine phosphoramidate nucleotides as non-toxic anti-HCV agents that upon intracellular metabolism deliver multiple nucleoside inhibitor 5'-triphosphates (NI-TP).Methods: A variety of β-D-2'-C-methyl-4-N-OH-C prodrugs were synthesized and evaluated for: 1) inhibition of HCV viral replication in Huh7 replicon cells; 2) cytotoxicity in various cell lines; 3) cellular pharmacology in both Huh7 cells and primary human hepatocytes; and 4) IC50 values for three NI-TPs were determined against the HCV NS5B polymerase (Pol).Results: The β-D-2'-C-methyl-4-N-OH-C prodrugs were pan-genotypic, effective against various HCV resistant mutants and resistant variants could not be selected in a Huh7 based replicon system.Upon cellular entry, β-D-2'-C-methyl-4-N-OH-C prodrugs were metabolized to generate three distinct NI-TPs: 2'-C-methyl-CTP, 2'-C-methyl-UTP and 2'-C-methyl-4-N-OH-CTP.The two former NI-TPs are well characterized for their anti-HCV activity, but interestingly, we found that 2'-C-methyl-4-N-OH-CTP can be incorporated both as a cytidine and uridine analog with HCV pol.We also established that 2'-C-methyl-4-N-OH-CTP was able to effectively inhibit RNA polymerization when pre-incubated with purified HCV pol, but was outcompeted when co-incubated with natural CTP and UTP substrates.Conclusion: The discovery of these novel β-D-2'-C-methyl-4-N-OH-C prodrugs could have important clinical implications based on their unique ability to deliver a cascade of three active pan-genotypic NI-TPs intracellularly with distinctive incorporation profiles and high barrier to resistance.
Regional distribution of pulmonary arterial blood flow in acute asthma
Authors: F. S. Mishkin
Journal: JAMA (1968)

In 19 adult patients, during an acute asthmatic attack, the regional distribution of pulmonary arterial blood flow was measured by means of radioisotope lung scanning after the intravenous injection of iodinated I 131 serum albumin aggregated. All but one patient had focal perfusion abnormalities. In two of six patients examined during a repeat attack, the abnormalities appeared to be localized in the same regions, while in three other patients, different areas of the pulmonary circulation were affected. In the remaining patient, scans were normal during the two consecutive acute asthmatic attacks. In all six patients studied during remission, the scan pattern returned towards normal. These findings are of importance in the differential diagnosis of acute bronchial asthma, chronic obstructive emphysema, and pulmonary embolism.
Highlights
Journal: JAMA (2015)

Research NSAIDs With Muscle Relaxants or Opioids for Low Back Pain 1572Treatment of low back pain with multiple concurrent medications-often nonsteroidal antiinfl ammatory drugs (NSAIDs), a skeletal muscle relaxant, and an opioid-is common; however, whether this results in better pain relief or improved functional outcomes is unclear.In a randomized 3-group study that enrolled 323 patients with acute, nontraumatic, and nonradicular low back pain presenting for care at an urban emergency department, Friedman and colleagues found that adding cyclobenzaprine or oxycodone plus acetaminophen to naproxen alone did not improve functional outcomes or pain at 7 days' follow-up.Continuing Medical Education jamanetworkcme.com Safety of Repeat Tdap Vaccination in Pregnancy 1581It is recommended that pregnant women receive tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during each pregnancy-regardless of prior immunization status.Sukumaran and colleagues assessed the association of Tdap vaccination with acute events and adverse birth outcomes in a retrospective cohort study involving 29 155 pregnant women who had received the Tdap vaccine within 2 years, within 2 to 5 years, or more than 5 years of a prior tetanus-containing vaccine.The authors found no increased risk of acute maternal events (fever, allergy, or local reactions) or adverse birth outcomes (small for gestational age, preterm delivery, or low birth weight) associated with the interval between tetanus-containing vaccinations.
Hypertensive crisis with bilateral bullous retinal detachment
Authors: L. L. Stropes
Journal: JAMA (1977)

MALIGNANT hypertension develops in approximately 1% of patients with essential hypertension. Patients may have a variety of signs and symptoms related to neurologic, cardiac, renal, or gastrointestinal systems. Presentation of malignant hypertension as near total blindness with bilateral bullous retinal detachments is exceedingly rare, but this case underscores that all physicians, regardless of specialty, must take blood pressure measurements in all patients regardless of their complaints. <h3>Report of a Case</h3> In a 19-year-old man, blurred vision developed three weeks prior to admission to the hospital. He was seen by an ophthalmologist who diagnosed optic neuritis and prescribed prednisone, 20 mg every other day. His vision transiently improved, but then deteriorated to the point where he could differentiate only light from dark. He was referred to Indiana University Medical Center for further examination. He had a blood pressure reading of 300/170 mm Hg, and the visual acuity was impairedbilaterally so that
Critical Windows of Exposure for Children's Health: Cancer in Human Epidemiological Studies and Neoplasms in Experimental Animal Models
Authors: Lucy M. Anderson, Bhalchandra A. Diwan, Nicola T. Fear, Eve Roman
Journal: Environmental Health Perspectives (2000)

In humans, cancer may be caused by genetics and environmental exposures; however, in the majority of instances the identification of the critical time window of exposure is problematic.The evidence for exposures occurring during the preconceptional period that have an association with childhood or adulthood cancers is equivocal.Agents definitely related to cancer in children, and adulthood if exposure occurs in utero, include: maternal exposure to ionizing radiation during pregnancy and childhood leukemia and certain other cancers, and maternal use of diethylstilbestrol during pregnancy and clear-cell adenocarcinoma of the vagina of their daughters.The list of environmental exposures that occur during the perinatal/postnatal period with potential to increase the risk of cancer is lengthening, but evidence available to date is inconsistent and inconclusive.In animal models, preconceptional carcinogenesis has been demonstrated for a variety of types of radiation and chemicals, with demonstrated sensitivity for all stages from fetal gonocytes to postmeiotic germ cells.Transplacental and neonatal carcinogenesis show marked ontogenetic stage specificity in some cases.Mechanistic factors include the number of cells at risk, the rate of cell division, the development of differentiated characteristics including the ability to activate and detoxify carcinogens, the presence of stem cells, and possibly others.Usefulness for human risk estimation would be strengthened by the study of these factors in more than one species, and by a focus on specific human risk issues.
Current Comment
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.
Authors: Michelle A. Ojemuyiwa, Fatima H. Karzai, Avani Atul Shah, Marc Robert Theoret, Nancy Harold, Guinevere Chun, Anna Couvillon, Andrea Borghese Apolo, Douglas K. Price, Ravi Amrit Madan, William Douglas Figg, James L. Gulley, William L. Dahut
Journal: Journal of Clinical Oncology (2014)

218 Background: Trebananib is an angiopoietin1/2 antagonist peptibody. Androgens stimulate expression of VEGF via activation of hypoxia inducible factor-a (HIFa). Androgen deprivation therapy (ADT) is associated with lower HIF1a gene expression in prostate cancer tissue. Dual targeting of the androgen and angiogenic axis represents a potential synergistic anti-angiogenic therapeutic approach in metastatic castration resistant prostate cancer (mCRPC). In this preliminary safety study we hypothesize that trebananib in combination with abiraterone will have a favorable tolerability and efficacy profile. Methods: Patients with mCRPC were treated with abiraterone 1000mg daily and prednisone 5 mg twice daily. Trebananib was administered intravenously every week, in escalating doses from 15mg/kg to 30mg/kg on days 1, 8, 15, and 22 every 28-days. Results: A total of 9 patients were enrolled. Three of nine patients had prior chemotherapy. The median age was 63.8 (63-71yrs). No dose limiting toxicities were observed. The most common grade ≥ 2 toxicities included limb edema (3/9), hyperglycemia (1/9), gastrointestinal (2/9), fatigue (2/9), hypertension (1/9), confusion (1/9), weight gain (1/9) and insomnia (2/9). 5/9 of patients had an overall PSA decline of &gt;30%. 8/9 patients were evaluable for response. Prior chemotherapy patients were on study for 1 and 3 months. No prior chemotherapy patients were treated for 1, 6, 9, 10, 10, and 17 months. Conclusions: Trebananib in combination with abiraterone is well tolerated and displayed an acceptable safety profile in patients with mCRPC. Based on this safety data a randomized phase II study randomizing chemotherapy-naïve mCRPC patients to either abiraterone/prednisone plus AMG 386 at 30mg/kg or abiraterone/prednisone is currently accruing at the NCI. Clinical trial information: NCIT01553188.